WO2001034642A3 - Control of neisserial membrane synthesis - Google Patents

Control of neisserial membrane synthesis Download PDF

Info

Publication number
WO2001034642A3
WO2001034642A3 PCT/US2000/031082 US0031082W WO0134642A3 WO 2001034642 A3 WO2001034642 A3 WO 2001034642A3 US 0031082 W US0031082 W US 0031082W WO 0134642 A3 WO0134642 A3 WO 0134642A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
methods
mutant
neisseria
control
Prior art date
Application number
PCT/US2000/031082
Other languages
French (fr)
Other versions
WO2001034642A2 (en
Inventor
Michael Apicella
Andrew Preston
Original Assignee
Univ Iowa Res Found
Michael Apicella
Andrew Preston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/439,226 external-priority patent/US6518037B2/en
Application filed by Univ Iowa Res Found, Michael Apicella, Andrew Preston filed Critical Univ Iowa Res Found
Priority to AU19175/01A priority Critical patent/AU1917501A/en
Publication of WO2001034642A2 publication Critical patent/WO2001034642A2/en
Publication of WO2001034642A3 publication Critical patent/WO2001034642A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention discloses a mutant Neisseria having extensive membrane blebbing, both an indicium and a cause of virulence in the gonococcus and meningococcus. Methods are disclosed for making and characterizing the mutant, bmrRS. Methods are disclosed for isolating bmrRS membranes for use as a vaccine. Methods are also disclosed for identifying proteins that are unique to the mutant Neisseria. Proteins coded for or under the control of the bmr locus are provided. Methods are also disclosed for the use of the unique mutant proteins for determining the virulence of clinical samples of N. gonorrhoeae and N. meningitidis. Methods are also disclosed for the screening of antibiotics targeted to virulent Neisseria.
PCT/US2000/031082 1999-11-12 2000-11-13 Control of neisserial membrane synthesis WO2001034642A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19175/01A AU1917501A (en) 1999-11-12 2000-11-13 Control of neisserial membrane synthesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16521799P 1999-11-12 1999-11-12
US09/439,226 1999-11-12
US09/439,226 US6518037B2 (en) 1999-11-12 1999-11-12 Two-component system that controls bacterial membrane synthesis
US60/165,217 1999-11-12

Publications (2)

Publication Number Publication Date
WO2001034642A2 WO2001034642A2 (en) 2001-05-17
WO2001034642A3 true WO2001034642A3 (en) 2001-11-22

Family

ID=26861200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031082 WO2001034642A2 (en) 1999-11-12 2000-11-13 Control of neisserial membrane synthesis

Country Status (2)

Country Link
AU (1) AU1917501A (en)
WO (1) WO2001034642A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2278446T3 (en) 1998-05-29 2007-08-01 Novartis Vaccines And Diagnostics, Inc. B / C COMBINED VACCINES AGAINST MENINGITIS.
CA2929348A1 (en) 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
RU2279889C2 (en) 2000-01-17 2006-07-20 Чирон С.Р.Л. OUTER MEMBRANE VESICLE VACCINE (OMV) CONTAINING PROTEINS OF SEROGROUP B N.Meningitis OUTER MEMBRANE
EP1322328B1 (en) 2000-07-27 2014-08-20 Children's Hospital & Research Center at Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP4993750B2 (en) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vesicular vaccine based on GNA1870 for broad protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
ES2557282T3 (en) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use
CA2733943A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (en) 2008-12-17 2011-09-28 Novartis AG Meningococcal vaccines including hemoglobin receptor
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
AU2010288240B2 (en) 2009-08-27 2014-03-27 Novartis Ag Hybrid polypeptides including meningococcal fHBP sequences
CA2772103A1 (en) 2009-08-27 2011-03-03 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
ES2443952T3 (en) 2009-09-02 2014-02-21 Novartis Ag Immunogenic compositions that include modulators of TLR activity
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
JP5960055B2 (en) 2009-10-27 2016-08-02 ノバルティス アーゲー Modified meningococcal fHBP polypeptide
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG181712A1 (en) 2009-12-15 2012-07-30 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CA2793510A1 (en) 2010-03-18 2012-02-16 Novartis Ag Adjuvanted vaccines for serogroup b meningococcus
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
JP2014529407A (en) 2011-08-31 2014-11-13 チルドレンズホスピタル アンド リサーチ センター オークランド Engineered sequences and methods of use for promoting antigen expression in Neisseria
RU2014135522A (en) 2012-02-02 2016-03-27 Новартис Аг Promoters for Enhanced Protein Expression at Meningococcus
JP2015517089A (en) 2012-03-08 2015-06-18 ノバルティス アーゲー In vitro efficacy assay for protein-based meningococcal vaccines
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
RU2662970C2 (en) 2012-09-18 2018-07-31 Новартис Аг Outer membrane vesicles
BR112015018877A2 (en) 2013-02-07 2017-08-22 Externautics Spa METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION, AND IMMUNOGENIC PHARMACEUTICAL COMPOSITION
CA2940447C (en) 2014-02-28 2023-07-11 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
US20180064801A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059625A1 (en) * 1998-05-19 1999-11-25 University Of Maryland Vaccine delivery system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059625A1 (en) * 1998-05-19 1999-11-25 University Of Maryland Vaccine delivery system

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BULYGIN, V. V. ET AL.: "Rotation of the Epsilon Subunit during Catalysis by Escherichia coli FoFsub1-ATP Synthase", J. BIOL. CHEM., vol. 273, no. 48, 27 November 1998 (1998-11-27), pages 31765 - 31769, XP002167182 *
MEADOW, P. M. ET AL.: "The Effect of Lipopolysaccharide Composition on the Ultrastructure of Pseudomonas aeruginosa", J. GEN. MICROBIOL., vol. 105, 1978, pages 23 - 28, XP000990980 *
PETTIT, R. K. ET AL.: "Characterization of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae", MOL. MICROBIOL., vol. 6, no. 6, 1992, pages 723 - 728, XP000990841 *
PRESTON, A. ET AL.: "A Two Component Regulatory System Involved in LOS Microheterogeneity in Neisseria gonorrhoeae", ABSTRACTS GRAL. MEET. ASM, vol. 96, 1996, pages 208, XP002167184 *
RAMÍREZ-ARCOS, S. ET AL.: "Expression and Interaction of the minCDE Genes of Neisseria gonorrhoeae", ABSTRACTS GRAL. MEET. ASM, vol. 99, June 1999 (1999-06-01), pages 352, XP002167181 *
SUZUKI, H. ET AL.: "Murein-Lipoprotein of Escherichia coli: A Protein Involved in the Stabilization of Bacterial Cell Envelope", MOL. GEN. GENET., vol. 167, 1978, pages 1 - 9, XP000990950 *
WATNICK, R. S. ET AL.: "Escherichia coli NusA is required for efficient RNA binding by phage HK022 Nun protein", PNAS, vol. 95, February 1998 (1998-02-01), pages 1546 - 1551, XP002167183 *
ZHOU D ET AL: "LIPOOLYGOSACHARIDE BIOSYNTHESIS IN NEISSERIA GONORRHOEAE: CLONING,IDENTIFICATION AND CHARACTERIZATION OF THE ALPHA1,5 HEPTOSYLTRANSFERASE 1 GENE (RFAC)", MOLECULAR MICROBIOLOGY,GB,BLACKWELL SCIENTIFIC, OXFORD, vol. 14, no. 4, 1994, pages 609 - 618, XP000770667, ISSN: 0950-382X *

Also Published As

Publication number Publication date
WO2001034642A2 (en) 2001-05-17
AU1917501A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
WO2001034642A3 (en) Control of neisserial membrane synthesis
EP1900818A3 (en) Neisserial antigens
WO2000071725A3 (en) Combination neisserial compositions
EP2270031A3 (en) Heterologous expression of neisserial proteins
EP1645631A3 (en) Neisseria antigens and compositions
EP1777233A3 (en) Gonococcal proteins and nucleic acids
CY1110540T1 (en) 85kDa ΑΝΤΙΓΟΝΟ NEISSERIAL
EP1144998A3 (en) Neisseria genomic sequences and methods of their use
ATE427756T1 (en) NEISSERIA MENINGITIDIS SERUM GROUP B AND C ANTIGENS AND COMPOSITIONS CONTAINING AN ADDITIONAL ANTIGEN
EP2279746A3 (en) Surface proteins in neisseria meningitidis
EP1852125A3 (en) Neisserial vaccine compositions and methods
AU2003288558A1 (en) Meningococcal vaccine based on outer membrane proteins porb2 and pora
WO2004063225A3 (en) Novel fibulin-like polypeptides
WO2004031233A3 (en) Novel chemokine-like polypeptides
WO2004063222A3 (en) Novel preadipocyte factor-1-like polypeptides
WO2004063223A3 (en) Notch-like polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase